Search

Your search keyword '"Kottler D"' showing total 158 results
Start Over Author "Kottler D"
158 results on '"Kottler D"'

4. Infections cutanées à Mycobacterium chelonae non iatrogènes : cohorte descriptive rétrospective multicentrique française

Author

Leymarie, A., primary, Thibon, P., additional, Bernigaud, C., additional, Claire, D., additional, Ouedraogo, E., additional, Lemaitre, N., additional, Lehericey, M., additional, Calugareanu, A., additional, Chosidow, O., additional, Drancourt, M., additional, Cribier, B., additional, Vanhaecke, C., additional, Dompmartin, A., additional, Goujon, E., additional, Allard, T., additional, Fouéré, S., additional, Lheure, C., additional, Cambau, E., additional, Robert, J., additional, Dupin, N., additional, Verdon, R., additional, and Kottler, D., additional

Published
2023
Full Text
View/download PDF

6. Efficacy, tolerance and acceptability of pulsed dye laser on facial and neckline telangiectasias in systemic scleroderma: a prospective open-label monocentric study in 21 patients.

Author

Kottler, D., Dupechez, L., Martin Silva, N., Boutemy, J., Dumont, A., Maigné, G., Aouba, A., and Dompmartin, A.

Subjects
*SYSTEMIC scleroderma, *DYE lasers, *PULSED lasers, *TELANGIECTASIA, *PATIENT satisfaction
Abstract

Facial and neckline telangiectasias have an underestimated yet important impact on quality of life of patients with systemic scleroderma (SSc). This monocentric, prospective, open-label, intra-patient comparative study was conducted in 21 consecutive patients with SSc. Patients underwent 4 sessions of PDL 8 weeks apart. A final quadruple assessment was performed by several raters 2 months after the last session, based on the following criteria: change in telangiectasia number; subjective improvement score (LINKERT scale); impact on the quality of life (QoL; SKINDEX score); visual analog pain scale; adverse effects (AEs), including treatment discontinuation for PDL-induced purpura and patient satisfaction. The mean telangiectasia number decreased by 5 (32%) at the end of the protocol. Eighteen patients (85.7%) reported an improvement or a strong improvement, versus 73.81% for the expert committee. Immediate session pain (mean = 3.4/10) was slightly less than overall pain (mean = 4.6/10). Ten patients (47%) experienced at least one AE (oozing/crusts, edema, epidermal blistering), including PDL-induced purpura in 3 patients (14%). AEs were mostly transient (<1 week) and mild (CTCAE grade 1). All QoL parameters improved after treatment, and 85% of patients were satisfied. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Étude VASCUL-R : validation prospective de 5 items en dermoscopie péri-unguéale prédisant une capillaroscopie normale au cours du phénomène de Raynaud

Author

Monfort, J.B., primary, Klejtman, T., additional, Lazareth, I., additional, Kottler, D., additional, Blaise, S., additional, Imbert, B., additional, Chaby, G., additional, Lok, C., additional, Maillard, H., additional, Beneton, N., additional, Journet, J., additional, Goujon, E., additional, Tella, E., additional, Jacquin, A., additional, Vicaut, E., additional, and Senet, P., additional

Published
2022
Full Text
View/download PDF

9. Sclérœdèmes de Buschke liés à une gammapathie monoclonale : série de 15 cas et revue de la littérature

Author

Hulin, M., primary, Arnulf, B., additional, Jachiet, M., additional, Harel, S., additional, Royer, B., additional, Chasset, F., additional, Fain, O., additional, Begon, E., additional, Carpentier, O., additional, Thomas Beaulieu, D., additional, Bessis, D., additional, Decaux, O., additional, Deroux, A., additional, Nicolas, D., additional, Poiraud, C., additional, Mascaro, J.M., additional, De Larrea, C.F., additional, Bladé, J., additional, Mozas, P., additional, Giavedoni, P., additional, Kottler, D., additional, Bouaziz, J.D., additional, and Mahévas, T., additional

Published
2022
Full Text
View/download PDF

11. Caractéristiques capillaroscopiques de l’acrocyanose

Author

Guelimi, R., primary, Monfort, J.B., additional, Chaby, G., additional, Lok, C., additional, Lazareth, I., additional, Maillard, H., additional, Beneton, N., additional, Kottler, D., additional, Blaise, S., additional, Imbert, B., additional, Journet, J., additional, Goujon, E., additional, Jacquin, A., additional, Tella, E., additional, Vicaut, E., additional, Klejtman, T., additional, and Senet, P., additional

Published
2022
Full Text
View/download PDF

13. PET/CT variants and pitfalls in malignant melanoma

Author

Aide, N, Iravani, A, Prigent, K, Kottler, D, Alipour, R, Hicks, RJ, Aide, N, Iravani, A, Prigent, K, Kottler, D, Alipour, R, and Hicks, RJ

Abstract

18F-FDG PET/CT plays an increasingly pivotal role in the staging and post-treatment monitoring of high-risk melanoma patients, augmented by the introduction of therapies, including tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICIs), that have novel modes of action that challenge conventional response assessment. Simultaneously, technological advances have been regularly released, including advanced reconstruction algorithms, digital PET and motion correction, which have allowed the PET community to detect ever-smaller cancer lesions, improving diagnostic performance in the context of indications previously viewed as limitations, such as detection of in-transit disease and confirmation of the nature of small pulmonary metastases apparent on CT.This review will provide advice regarding melanoma-related PET protocols and will focus on variants encountered during the imaging of melanoma patients. Emphasis will be made on pitfalls related to non-malignant diseases and treatment-related findings that may confound accurate interpretation unless recognized. The latter include signs of immune activation and immune-related adverse events (irAEs). Technology-related pitfalls are also discussed, since while new PET technologies improve detection of small lesions, these may also induce false-positive cases and require a learning curve to be observed. In these times of the COVID 19 pandemic, cases illustrating lessons learned from COVID 19 or vaccination-related pitfalls will also be described.

Published
2022

15. Spectre clinique et pronostic des vascularites cutanées survenant au cours de la maladie de Sjögren : une étude de cohorte multicentrique de 54 patients (étude VasCuSjo)

Author

Breillat, P., Le Guern, V., D’humieres, T., Battistella, M., Legendre, P., Lenormand, C., Kottler, D., Mathian, A., Jachiet, M., El Khalifa, J., Mahévas, T., Comarmond, C., Sene, D., Amoura, Z., Gottenberg, J.E., Mouthon, L., Bouaziz, J.D., Mariette, X., and Chasset, F.

Abstract

L’apparition d’une vascularite au cours de la maladie de Sjögren (SjD) est un signe d’activité dans le score Eular Sjögren Syndrome Disease Activity index (ESSDAI) et est associée au mauvais pronostic notamment en raison du risque accru de développer une hémopathie lymphoïde B. Elle est rapportée chez 9 à 15 % des patients, l’atteinte cutanée étant la plus fréquente (80 à 90 % des cas). Cependant, plusieurs types de vascularites cutanées (VC) ont été décrits au cours de la SjD, notamment les vascularites cryoglobulinémiques, hypergammaglobulinémiques et urticariennes. L’objectif était d’évaluer les caractéristiques cliniques, immunologiques et le pronostic des différents types de VC au cours de la SjD.

Published
2024
Full Text
View/download PDF

20. Myopathies inflammatoires induites par les immunothérapies : du diagnostic au traitement

Author

Weill, A., primary, Delyon, J., additional, Descamps, V., additional, Kottler, D., additional, Dinulescu, M., additional, Dupuy, A., additional, Célérier, P., additional, Nardin, C., additional, Aubin, F., additional, Le Corre, Y., additional, Heidelberger, V., additional, Maubec, E., additional, Malissen, N., additional, Troin, L., additional, Longvert, C., additional, Gounant, V., additional, Brosseau, S., additional, Pluvy, J., additional, Bonniaud, B., additional, Jeudy, G., additional, Leonard-Louis, S., additional, Doucet, L., additional, De Masson, A., additional, Baroudjan, B., additional, Hervier, B., additional, and Brunet-Possenti, F., additional

Published
2019
Full Text
View/download PDF

23. Efficacité et tolérance de la prednisone à 0,5 mg/kg/j en traitement initial de la pemphigoïde bulleuse

Author

Bastos, S., primary, Hebert, V., additional, Vassileva, S., additional, Patsatsi, A., additional, Meijer, J., additional, Quéreux, G., additional, Bedane, C., additional, Prost-Squarcioni, C., additional, Debardieux, S., additional, Oro, S., additional, Chaby, G., additional, D’Incan, M., additional, Litrowski, N., additional, Boulard, C., additional, Lunardon, L., additional, Kiritsi, D., additional, Jedlickova, H., additional, Feliciani, C., additional, Roussel, A., additional, Kottler, D., additional, Plantin, P., additional, Richard, M.-A., additional, Friedrichsen, L., additional, Abasq, C., additional, Duvert Lehembre, S., additional, Gottlieb, J., additional, Zebrowska, A., additional, Hofmann, S., additional, and Joly, P., additional

Published
2019
Full Text
View/download PDF

24. Profil du télédermatologue en France en 2019

Author

Bataille, M., primary, Mahé, E., additional, Vuong, V., additional, Dompmartin, A., additional, Richard, M.-A., additional, Debarbieux, S., additional, Doutre, M.-S., additional, Friedel, J., additional, Ottavy, F., additional, Jouan, N., additional, Pépin, E., additional, Pistorius, V., additional, Perier, M., additional, Brenaut, E., additional, Kottler, D., additional, Hirsch, G., additional, Hubiche, T., additional, Morand, J.-J., additional, Ollivaud, L., additional, Gallais, V., additional, Gautier, M.-S., additional, Carvalho, P., additional, and Duong, T.-A., additional

Published
2019
Full Text
View/download PDF

28. Perioral skin thickening revealing AL amyloidosis.

Author

Billard, K., Arnulf, B., Kottler, D., Mirouse, A., Harel, S., Royer, B., Bagot, M., Jachiet, M., Bouaziz, J.D., and Mahévas, T.

Subjects
MONOCLONAL gammopathies, AMYLOIDOSIS, CARDIAC amyloidosis, IMMUNOGLOBULIN light chains, BONE marrow examination
Abstract

AL amyloidosis (ALA) is a rare systemic condition resulting from the extracellular deposition of monoclonal gammopathy light chains. Skin and digestive tract biopsies allowed the diagnosis of ALA. [Extracted from the article]

Published
2022
Full Text
View/download PDF

29. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut‐off values for defining mild, moderate and severe types of bullous pemphigoid.

Author

Masmoudi, W., Vaillant, M., Vassileva, S., Patsatsi, A., Quereux, G., Moltrasio, C., Abasq, C., Prost‐Squarcioni, C., Kottler, D., Kiritsi, D., Litrowski, N., Plantin, P., Friedrichsen, L., Zebrowska, A., Duvert‐Lehembre, S., Hofmann, S., Ferranti, V., Jouen, F., Joly, P., and Hebert, V.

Subjects
BULLOUS pemphigoid, PHYSICIANS, ENZYME-linked immunosorbent assay, INTRACLASS correlation, DIAGNOSIS, INTER-observer reliability
Abstract

Summary: Background: The Bullous Pemphigoid Disease Area Index (BPDAI) score has been proposed to provide an objective measure of bullous pemphigoid (BP) activity. Objectives: The objective of this study was to calculate BPDAI cut‐off values defining mild, moderate and severe BP. We also aimed to assess the interrater reliability and correlation with the number of daily new blisters, and anti‐BP180 and anti‐BP230 antibodies. Methods: Severity scores were recorded by two blinded investigators. Anti‐BP180 and anti‐BP230 antibodies were measured using an enzyme‐linked immunosorbent assay (ELISA). Cut‐off values defining mild, moderate and severe subgroups were calculated based on the 25th and 75th percentiles of the BPDAI score. Results: In total, 285 patients with BP were enrolled from 50 dermatology departments in Europe. Median BPDAI activity was 37·5 points (range 0–164). Cut‐off values corresponding to the first and third quartiles of the BPDAI score were 20 and 57, respectively; thus, these values were used to define mild (≤ 19), moderate (≥ 20 and ≤ 56) and severe (≥ 57) BP. The median BPDAI score for patients with ≤ 10 daily new blisters was 26 [interquartile range (IQR) 17–45], and for patients with > 10 daily new blisters the median score was 55 (IQR 39–82). The BPDAI intraclass correlation coefficient measured at baseline was 0·97 and remained higher than 0·90 up to month 6. The improvement in the BPDAI score was correlated with the absolute decrease in anti‐BP180 ELISA value (Spearman's rank r = 0·34, P < 0·004), but not with anti‐BP230 antibodies (r = 0·17, P = 0·15). Conclusions: This study suggests cut‐off values of 20–57 for BPDAI to distinguish mild, moderate and severe BP, and confirms that it is a robust tool to assess BP severity precisely. What is already known about this topic?The Bullous Pemphigoid Disease Area Index (BPDAI) is a new scoring system to measure bullous pemphigoid (BP) activity.The use of this score in clinical practice is limited by the absence of cut‐off values. What does this study add?Cut‐off values of 20 and 57 were established to distinguish mild, moderate and severe BP using the BPDAI.These disease activity subgroups could help physicians in the management of patients with BP. What are the clinical implications of this work?This study classified patients with BP into three subgroups (mild, moderate and severe) based on the BPDAI score.The BPDAI score is a robust tool to assess BP activity accurately, both at diagnosis and during the course of the disease, and could help physicians tailor treatment to disease activity, thereby providing better management of patients with BP. Linked Comment: Blome and Klein. Br J Dermatol 2021; 184:997–998. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Calcul des valeurs seuils du score BPDAI (Bullous Pemphigoid Disease Area Index) définissant les formes légères, modérées et sévères de la pemphigoïde bulleuse

Author

Masmoudi, W., primary, Hebert, V., additional, Quéreux, G., additional, Bedane, C., additional, Prost-Squarcioni, C., additional, Debarbieux, S., additional, Oro, S., additional, Chaby, G., additional, D’incan, M., additional, Litrowski, N., additional, Boulard, C., additional, Roussel, A., additional, Kottler, D., additional, Abasq, C., additional, Richard, M.-A., additional, Duvert-Lehembre, S., additional, Gottlieb, J., additional, Plantin, P., additional, and Joly, P., additional

Published
2018
Full Text
View/download PDF

36. Histiocytose indéterminée

Author

Kouby, F., primary, Kottler, D., additional, Deschamps, L., additional, Jachiet, M., additional, Marhino, E., additional, Battistella, M., additional, Ortonne, N., additional, Fite, C., additional, Emile, J.-F., additional, Bouaziz, J.-D., additional, and Descamps, V., additional

Published
2017
Full Text
View/download PDF

38. Caractérisation chimique et topographique des dépôts cutanés au cours de la calciphylaxie urémique

Author

Colboc, H.C., primary, Moguelet, P., additional, Bazin, D., additional, Carvalho, P., additional, Dillies, A.S., additional, Maillard, H., additional, Kottler, D., additional, Goujon, E., additional, Panaye, M., additional, Frochot, V., additional, Weil, R., additional, Letavernier, E., additional, Jouanneau, C., additional, Daudon, M., additional, and Senet, P., additional

Published
2017
Full Text
View/download PDF

39. Infections cutanées à Mycobacterium chelonaenon iatrogènes : cohorte descriptive rétrospective multicentrique française

Author

Leymarie, A., Thibon, P., Bernigaud, C., Claire, D., Ouedraogo, E., Lemaitre, N., Lehericey, M., Calugareanu, A., Chosidow, O., Drancourt, M., Cribier, B., Vanhaecke, C., Dompmartin, A., Goujon, E., Allard, T., Fouéré, S., Lheure, C., Cambau, E., Robert, J., Dupin, N., Verdon, R., and Kottler, D.

Abstract

Les infections cutanées dues à M. chelonae(MC) sont principalement secondaires à des inoculations iatrogènes mais certains cas sont décrits en dehors de tout acte invasif. L’objectif était de décrire les caractéristiques cliniques, microbiologiques, histologiques et thérapeutiques des patients présentant une infection cutanée à MC non iatrogène.

Published
2023
Full Text
View/download PDF

49. Angiodermite nécrotique

Author

Kottler, D.

Abstract

L’angiodermite nécrotique est une forme d’ulcères de jambe très douloureux non liés à une insuffisance veineuse ou artérielle, dont la fréquence est probablement sous-estimée. Sa physiopathologie est en lien avec l’hypertension artérielle chronique. Sa prise en charge repose actuellement en première intention sur la greffe cutanée qui permet une antalgie rapide et souvent l’arrêt de la progression lésionnelle. Les mesures associées telles que le contrôle tensionnel et la compression en cas d’insuffisance veineuse associée sont indispensables.

Published
2023
Full Text
View/download PDF

50. Efficacité et tolérance de la prednisone à 0,5mg/kg/j en traitement initial de la pemphigoïde bulleuse

Author

Bastos, S., Hebert, V., Vassileva, S., Patsatsi, A., Meijer, J., Quéreux, G., Bedane, C., Prost-Squarcioni, C., Debardieux, S., Oro, S., Chaby, G., D’Incan, M., Litrowski, N., Boulard, C., Lunardon, L., Kiritsi, D., Jedlickova, H., Feliciani, C., Roussel, A., Kottler, D., Plantin, P., Richard, M.-A., Friedrichsen, L., Abasq, C., Duvert Lehembre, S., Gottlieb, J., Zebrowska, A., Hofmann, S., and Joly, P.

Abstract

Le traitement de référence de la pemphigoïde bulleuse (PB) est la corticothérapie locale très forte. Celle-ci est parfois difficile à réaliser en pratique. Pour cette raison, les guidelines européennes ont récemment proposé la prednisone orale à la dose de 0,5mg/kg/j comme traitement alternatif à la corticothérapie locale. On a montré que cette dose de 0,5mg/kg/j est aussi efficace que la corticothérapie locale dans les PB pauci-bulleuses, mais ceci n’a jamais été évaluée dans les PB multi-bulleuses. L’objectif était d’en évaluer l’efficacité et la tolérance.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results